Technical Update, Leadership Appointments, Therapy Approvals, Notifications, and Clinical Trial Results - Analyst Notes on Biogen, Medivation, BioMarin, Acorda and Targacept

NEW YORK, July 17, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Biogen Idec Inc. (NASDAQ: BIIB), Medivation, Inc. (NASDAQ: MDVN), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Acorda Therapeutics, Inc. (NASDAQ: ACOR) and Targacept, Inc. (NASDAQ: TRGT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4882-100free.

--
Biogen Idec Inc. Analyst Notes
On July 14, 2014, Biogen Idec Inc.'s (Biogen Idec) stock went down slightly by 0.77% to end the day at $319.75 compared to the previous day's closing price at $322.22. The Company's stock increased by 3.14% over the past one trading month compared to the Nasdaq Composite which rose 3.00% during the same period. The full analyst notes on Biogen are available to download free of charge at:

http://www.analystsreview.com/Jul-17-2014/BIIB/report.pdf

--
Medivation, Inc. Analyst Notes
On July 10, 2014, Medivation, Inc. (Medivation) announced the appointment of Dawn Svoronos as Chief Commercial Officer. According to the Company, in the new role, she will be responsible for leading the Company's commercial organization on an interim basis and will participate in the Company's search for a permanent Chief Commercial Officer. Cheryl Cohen, Medivation's former Chief Commercial Officer, has left the Company to pursue other opportunities. "We thank Cheryl for her years of service to Medivation and wish her the best," said David Hung, M.D., President and CEO of Medivation. "We are fortunate to have Dawn Svoronos, a seasoned executive with significant commercial expertise, step in on an interim basis to lead Medivation's commercial operations." Ms. Svoronos has had more than 30 years of pharmaceutical industry experience spanning the U.S., Europe, Asia and Canada. The full analyst notes on Medivation are available to download free of charge at:

http://www.analystsreview.com/Jul-17-2014/MDVN/report.pdf

--
BioMarin Pharmaceutical Inc. Analyst Notes
On July 7, 2014, BioMarin Pharmaceutical Inc. (BioMarin) announced that Health Canada has approved VIMIZIM™ (elosulfase alfa) for long-term enzyme replacement therapy in patients with a confirmed diagnosis of mucopolysaccharidosis IVA or Morquio A syndrome. "The Health Canada approval of VIMIZIM is a significant milestone for BioMarin, and for Canadians living with Morquio A and their families," said Hank Fuchs, M.D., Chief Medical Officer of BioMarin. "The approval of VIMIZIM firmly establishes our leadership in advancing important therapies for the treatment of MPS diseases. We will continue to build on our extensive scientific and clinical knowledge of lysosomal storage disorders to develop therapies for other rare genetic diseases." The approval makes VIMIZIM as the first and only pharmaceutical treatment option available in Canada for children and adults living with this severely debilitating, progressive and life-limiting disorder. The full analyst notes on BioMarin are available to download free of charge at:

http://www.analystsreview.com/Jul-17-2014/BMRN/report.pdf

--
Acorda Therapeutics, Inc. Analyst Notes
On June 26, 2014, Acorda Therapeutics, Inc. (Acorda) announced that it has received notification in relation to Actavis Laboratories FL, Inc.'s submission of an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) requesting permission to manufacture and market a generic version of AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg. Acorda informed that it is reviewing the Notice Letter and has 45 days from the date of receipt to commence a patent infringement lawsuit against Actavis Laboratories FL, Inc. in order to trigger a statutory stay period under the Hatch-Waxman Act, which would restrict FDA's decision to approve an ANDA until July 2017 at the earliest, unless a district court issues a decision adverse to all of Acorda's asserted Orange Book patents prior to that date. The full analyst notes on Acorda are available to download free of charge at:

http://www.analystsreview.com/Jul-17-2014/ACOR/report.pdf

--
Targacept, Inc. Analyst Notes
On July 14, 2014, Targacept, Inc. (Targacept) announced top-line results from a Phase 2b monotherapy clinical trial of TC-1734 as a treatment for mild to moderate Alzheimer's disease. The Company informed that in the trial TC-1734 did not meet the objective of showing superiority to donepezil, the marketed medication most often prescribed for Alzheimer's disease, after 52 weeks of treatment. "We are disappointed for Alzheimer's disease patients and their families. We designed a rigorous study to provide a definitive answer on whether TC-1734 could be a better treatment option than the current standard of care in what has been a very difficult disease area for the development of novel therapeutics. Based on these results, we do not intend to invest in further development of TC-1734," commented Dr. Stephen A. Hill, Targacept's President and CEO. "I want to thank the investigators, patients and my colleagues at Targacept for their efforts." The full analyst notes on Targacept are available to download free of charge at:

http://www.analystsreview.com/Jul-17-2014/TRGT/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review